Miscellaneous Urogenital Disorders

Risk of Acute Kidney Injury With SGLT2 Inhibitors Investigated

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) do not appear to increase the risk of acute kidney injury (AKI), according to the findings of a recently published systematic review and meta-analysis. To evaluate the risk of AKI with these agents, study authors reviewed literature analyzing the effect of SGLT2is on renal adverse events compared with placebo or other…

Renal Impairment Labeling Updates for Sofosbuvir-Based HCV Therapies

The FDA has approved updated labeling for Epclusa (sofosbuvir/velpatasvir), Harvoni (ledipasvir/sofosbuvir) and Vosevi (sofosbuvir/velpatasvir/voxilaprevir) to include updated information regarding treatment of patients with hepatitis C virus (HCV) who have severe renal impairment including those with end stage renal disease who are on dialysis.